



UNITED STATES DEPARTMENT OF COMMERCE United States Patient and Trademark Office Adhese COMMERSHOWER FOR PATENTS P.O. Box 168 Advantage, Viguia 22313-0450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO
09/738,927	12/13/2000	Robin R. Miles	IL-10404	1809
7.	990 01/22/2004		EXAM	INER
Alan H. Thompson			DIAMOND, ALAN D	

Assistant Laboratory Counsel Lawrence Livermore National Laboratory P.O. Box 808, L-703 Livermore, CA 94551 DIAMOND, ALAN D

ART UNIT PAPER NUMBER

DATE MAILED: 01/22/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/738,927	MILES, ROBIN R
Office Action Summary	Examiner	Art Unit
	Alan Diamond	1753
The MAILING DATE of this communication Period for Reply	on appears on the cover sheet w	ith the correspondence address
A SHORTENED STATUTORY PERIOD FOR IT. THE MANUNICAT THIS COMMUNICAT Detention of time may be available under the provisions of 37 often 50 (6) MONTHS from the making date of this commission if they provide for may be available under the provisions of 37 often 50 (6) MONTHS from the making date of this commission if they provide for may be available under the finite from this (6) MONTHS from the manual provisions of 37 often 50 MONTHS from the second provide for many with its part of the control provide for many with the part of the control provide for many with the second provided from the manual control part of the second provided from the manual control part of the second provided from the manual control part of the second provided from the manual control part of the second par	ION. JPR 1 139(a). In no event, however, may a lor. In a reply within the statutory minimum of this period will apply and will expire 50% (6) MO restriction outside the application to become A	reply be timely filed ity (20) days will be considered timely. NTHS from the mailing date of this communication. BANDONED SS U.S. C. \$130.
1) Responsive to communication(s) filed on	08 December 2003.	
2a)⊠ This action is FINAL. 2b)□	This action is non-final.	
 Since this application is in condition for a closed in accordance with the practice ur 	liowance except for formal mat nder Ex parte Quayle, 1935 C.I	ters, prosecution as to the merits is D. 11, 453 O.G. 213.
Disposition of Claims	,	
4) Claim(s) 1.f1 is/are pending in the applic 4a) Of the above claim(s) is/are wifting 5 Claim(s) 1.f1 is/are rejected. 6) Claim(s) 1.f1 is/are rejected. 7 Claim(s) is/are objected to. 8) Claim(s) are subject to restriction.	thdrawn from consideration.	
Application Papers		
9)☐ The specification is objected to by the Ext 10)☒ The drawing(s) filed on <u>08 December 200</u> Applicant may not request that any objection I Replacement drawing sheet(s) including the c 11)☐ The oath or declaration is objected to by t	3 is/are: a)⊠ accepted or b) to the drawing(s) be held in abeya correction is required if the drawing	nce. See 37 CFR 1.85(a). g(s) is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. §§ 119 and 120		
120 Acknowledgment is made of a claim for in Mark More of None of N	ments have been received. ments have been received in A priority documents have been rureau (PCT Rule 17.2(a)), a list of the certified copies not mestic priority under 35 U.S.C, he first sentence of the specific provisional application has b	Application No
14) Acknowledgment is made of a claim for do reference was included in the first sentence.	mestic priority under 35 U.S.C. of the specification or in an Ar	§§ 120 and/or 121 since a specific

13 14 Attachment(s) Application/Control Number: 09/738,927

Art Unit: 1753

DETAILED ACTION

Comments

- The Drawings filed December 8, 2003 have overcome the objection to the drawings.
- The objection to claims 5 and 7 because of informalities has been overcome by Applicant's amendment of the claims.
- The rejection of claim 5 under 35 USC 112, second paragraph, has been overcome by Applicant's amendment thereof.
- 4. The 35 USC 102 rejection of claims 8 and 9 over Milner et al has been overcome by Applicant's amendment of claim 8 so as to require the recited fluidic channel, said fluidic channel having a surface, at least one pair of interdigitated electrodes positioned on said surface of said fluidic channel with a space between said interdigitated electrodes, said at least one pair of interdigitated electrodes localized along said fluidic channel, with said at least one pair being located on the same surface of said fluidic channel, said interdigitated electrodes having electrode plates with a surface.
- 5. The rejections over Van Gerwen et al have been overcome by Applicant's amendment of claims 1 and 8 so as to require the recited fluidic channel, said fluidic channel having a surface, at least one pair of interdigitated electrodes positioned on said surface of said fluidic channel with a space between said interdigitated electrodes, said at least one pair of interdigitated electrodes localized along said fluidic channel, with said at least one pair being located on the same surface of said fluidic channel, said interdigitated electrodes having electrode plates with a surface.

Application/Control Number: 09/738,927
Art Unit: 1753

Claim Objections

 Claim 11 is objected to because of the following informalities: In claim 11, at each of lines 3 and 5, the word "on" should be changed to "one". Appropriate correction is required.

Claim Rejections - 35 USC § 112

- 7. The following is a quotation of the first paragraph of 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such life loans protein, and exact terms also nearlies any person silled in the art to which il pertains, or with which it is most nearly connected, to make and use the same and shall set furth the best mode contemplated by the invention of carriegio stall is interest.
- 8. Claims 1-11 are relected under 35 U S.C. 112, first peragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had cossession of the claimed invention.

In claim 1, at lines 11-13, the newly added recitation that *antibodies immobilized on said surface of said electrode plates and immobilized in said space between said interdigitated electrodes, wherein said pathogens carried by said fluid attach to said immobilized antibodies* is not supported by the specification, as originally filed. The same applies to dependent claims 2-7. It is suggested that lines 11-13 be deleted from claim 1.

In claim 8, at lines 12-14, the newly added recitation that "antibodies immobilized on said surface of said electrode plates and immobilized in said space between said interdigitated electrodes, wherein said pathogens carried by said fluid attach to said Application/Control Number: 09/738,927
Art Unit: 1753

immobilized antibodies" is not supported by the specification, as originally filed. The same applies to dependent claims 9-11. It is suggested that lines 12-14 be deleted from claim 8

Claim Rejections - 35 USC § 112

- The following is a quotation of the second paragraph of 35 U.S.C. 112:
 The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- Claims 1-11 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claim 1, at line 14, the term "across electrode plates" should be changed to "across said electrode plates" because there are now previously defined electrode plates in claim 1. The same applies to dependent claims 2-7.

Claim 8 is now indefinite because the term "said pathogens" at line 3 and bridging lines 13 and 14 lack positive antecedent support in claim 8 itself. It is suggested that "pathogens" at line 3 be changed to "particles". As noted above in the instant Office action, lines 12-14 of claim 8 should be deleted. The same applies to dependent claims 9-11.

Claim 8 is also now indefinite because it is not clear what is meant by "the said" at 17. It is suggested that "the" be deleted from line 17. The same applies to decendent claims 9-11.

Claim 10 is now confusing because the limitation "wherein said electrodes comprise plates of interdigitated electrodes" at lines 1-2 is already present in parent claim 8 due to the fact that claim 8 has been amended so as to recite that the interdigitated electrodes have plates. It is suggested that the term "wherein said electrodes comprise plates of interdigitated electrodes and" be deleted from lines 1-2 of claim 10.

Double Patenting

11. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (so policy reflected in the statute) as as to prevent the unjustified or improper timevise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See In C. Goodman, 11 F.3d. 1046, 29 USPO.24 2010 (Fed. Cir. 1935); In re. Longt, 759 F.2d 887, 225 USPO.24 2010 (Fed. Cir. 1953); In re. Longt, 759 F.2d 887, 225 USPO.24 2010 (Fed. Cir. 1955); In re. Van Orumi, 868 F.2d 387, 214 USPO.261 (CCPA. 1950).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

12. Claims 1-11 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 10-28 of copending Application No. 09/737,542. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of said copending application further include antibodies on the spaced electrodes. However, the presence of such antibodies are not excluded by the comprising language of the instant claims.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

13. Claims 1-11 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-9 of copending Application No. 09/993,870. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of said copending application further include antibodies on the spaced electrodes. However, the presence of such antibodies are not excluded by the comprising language of the instant claims.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

14. Claims 1-11 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over all of the claims of copending Application No. 09/738,461. Although the conflicting claims are not identical, they are not patentably distinct from each other because the ionic label that is trapped in the electric field of the claims of said copending application is not excluded by the comprising language of the instant claims.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Response to Arguments

 Applicant's arguments filed December 8, 2003 have been fully considered but they are not persuasive.

With respect to all of the above provisional obviousness-type double patenting rejections, Applicant states that he will await further official action. It is the Examiner's Application/Control Number: 09/738,927 Art Unit: 1753

. . .

position that said provisional obviousness-type double patenting rejections are proper and therefore have been maintained.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in
this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP

§ 708.07(a). Applicant is reminded of the extension of time policy as set forth in 37
CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the cate of this final action.

 Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alan Diamond whose telephone number is 571-272-1338. The examiner can normally be reached on Monday through Friday, 5:30 a.m. to 2:00 p.m. ET.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nam. Nguyen can be reached on 571-272-1342. The fax phone number for the organization where this application or proceeding is assigned is (703) 672-9306. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-

Alan Diamond Primary Examiner

Art Unit 1753

Alan Diamond January 15, 2004

. . . .